GFA
ABBV icon

Gallagher Fiduciary Advisors’s AbbVie ABBV Stock Holding History

Gallagher Fiduciary Advisors’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.39M Sell
5,508
-52
-0.9% -$11.2K 0.05% 87
2026
Q1 		$1.21M Buy
5,560
+56
+1% +$12.4K 0.05% 64
2025
Q4 		$1.26M Buy
5,504
+184
+3% +$41.9K 0.04% 81
2025
Q3 		$1.23M Buy
5,320
+69
+1% +$14.1K 0.05% 68
2025
Q2 		$975K Buy
5,251
+205
+4% +$38.1K 0.04% 77
2025
Q1 		$1.06M Buy
5,046
+205
+4% +$39.9K 0.03% 83
2024
Q4 		$860K Buy
4,841
+405
+9% +$74.5K 0.17% 69
2024
Q3 		$876K Buy
4,436
+1,803
+68% +$336K 0.18% 63
2024
Q2 		$452K Sell
2,633
-137
-5% -$22.7K 0.1% 110
2024
Q1 		$505K Sell
2,770
-356
-11% -$61.4K 0.02% 111
2023
Q4 		$485K Buy
3,126
+124
+4% +$18.1K 0.02% 106
2023
Q3 		$447K Sell
3,002
-203
-6% -$29.8K 0.04% 104
2023
Q2 		$432K Buy
3,205
+164
+5% +$24K 0.03% 133
2023
Q1 		$485K Buy
+3,041
New +$465K 0.04% 123

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Gallagher Fiduciary Advisors's ABBV Position: Q2 2026 in Review

Gallagher Fiduciary Advisors reduced its AbbVie (ABBV) stake by 0.94% in Q2 2026, selling an estimated $11.2K and leaving 5,508 shares worth $1.39M. The position accounts for 0.05% of the portfolio, ranked #87.

Gallagher Fiduciary Advisors first reported a position in ABBV in Q1 2023 and has held it in 14 quarters since. 4,201 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Gallagher Fiduciary Advisors held 5,508 shares of AbbVie worth $1.39M as of Q2 2026.
  • Gallagher Fiduciary Advisors sold 52 AbbVie shares in Q2 2026, an estimated $11.2K.
  • AbbVie made up 0.05% of Gallagher Fiduciary Advisors's portfolio in Q2 2026, its #87 holding.
  • Gallagher Fiduciary Advisors first reported a position in AbbVie in Q1 2023 and has held it in 14 quarters since.
  • 4,201 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Gallagher Fiduciary Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.